AZD2014 is a highly potent, selective and ATP-competitive mTOR inhibitor (IC₅₀ = 2.8 nM). It displays a high level of selectivity against other members of the PIKK family (IC₅₀ against PI3K isoforms α, β, γ, δ = 3.8 µM, >30 µM, >30 µM and >29 µM, respectively) and is inactive against a general panel of over 200 kinases when tested at 10 µM. AZD2014 inhibits both mTORC1 and mTORC2 in vitro (pS6 (S^235/236 ) IC₅₀ = 0.2 µM, pAKT (S⁴⁷³) IC₅₀ = 0.08 µM) and has shown dose-dependent tumor growth inhibition in a mouse MCF7 xenograft model alongside modulation of mTORC1 and mTORC2 biomarkers. Different from AZD8055, AZD2014 shows consistent exposure in rodents and a low turnover in human hepatocyte incubations. It is in phase I clinical development for advanced solid malignancies.

How to Use:

In vitro: AZD2014 was used at 2.5-5 µM concentration in vitro and cellular assays.

In vivo: AZD2014 was orally dosed to mice at 2.5-20 mg/kg once or twice per day to inhibit tumor growth.

Reference:

1. 1.  Guichard SM, at al. AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer. (2012) AACR Annual Meeting: Chicago, Abstract 917.
2. 2.  Pike KG, et al. Optimization of potent and  selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014. (2013) Bioorg Med Chem Lett. In press.

Products are for research use only. Not for human use.